brief
review
limit
scope
focus
technic
develop
practic
interest
concern
construct
hybridoma
expans
larg
scale
product
monoclon
antibodi
procedur
survey
yet
routin
appli
promis
highlight
tactic
improv
fusion
effici
product
antibodi
vitro
use
chemic
defin
cultur
media
attempt
gener
antibodi
murin
especi
human
beginn
hybridoma
technolog
plan
use
soon
awar
current
trend
beyond
classic
technolog
trend
care
consid
make
basic
decis
exampl
cell
line
use
fusion
partner
clear
new
avenu
explor
success
mous
rat
hybridoma
longer
altern
monoclon
antibodi
speci
eg
human
within
realm
possibl
said
brief
review
limit
scope
focus
technic
develop
practic
interest
concern
construct
hybridoma
expans
larg
scale
product
monoclon
antibodi
procedur
survey
yet
routin
appli
promis
highlight
tactic
improv
fusion
effici
product
antibodi
vitro
use
chemic
defin
cultur
media
attempt
gener
antibodi
murin
especi
human
beginn
hybridoma
technolog
plan
use
soon
awar
current
trend
beyond
classic
technolog
trend
care
consid
make
basic
decis
exampl
cell
line
use
fusion
partner
clear
new
avenu
explor
success
mous
rat
hybridoma
longer
altern
monoclon
antibodi
speci
eg
human
within
realm
possibl
said
sinc
introduct
hybridoma
technolog
kshler
milstein
consider
effort
invest
refin
product
monoclon
antibodi
basic
research
clinic
applic
much
also
learn
structur
genet
antibodi
studi
homogen
popul
molecul
teillaud
et
al
depinho
et
al
recent
year
use
monoclon
antibodi
clinic
procedur
increas
area
diagnost
test
monoclon
select
produc
reagent
desir
specif
thu
yield
reliabl
resuit
therapeut
applic
still
trial
stage
part
encourag
offer
hope
new
effect
treatment
mani
disord
recent
antibodysecret
b
lymphocyt
prepar
almost
exclus
immun
host
antigen
interest
desir
cell
recov
host
dissoci
spleen
lymphat
tissu
procedur
obviou
limit
studi
substanc
immunogen
anim
host
eg
macromolecul
normal
found
host
ethic
reason
use
immun
human
studi
interact
occur
rest
b
lymphocyt
transform
secret
cell
advanc
progress
made
toward
develop
vitro
immun
procedur
applic
procedur
somewhat
limit
becom
common
need
altern
vivo
immun
becom
clearer
earli
year
hybridoma
technolog
much
emphasi
place
upon
understand
structur
antibodi
mechan
control
product
anim
model
cell
use
extens
introduct
murin
myeloma
fusion
partner
shulman
et
al
produc
heavi
light
chain
allow
investig
produc
hybridoma
secret
antibodi
encod
gene
receiv
b
lymphocyt
partner
fusion
part
b
lymphocyt
deriv
immun
mice
often
balbc
produc
mous
mous
hybrid
similar
investig
human
monoclon
antibodi
hinder
lack
suitabl
human
myeloma
fusion
partner
effort
overcom
limit
signific
focu
research
monoclon
antibodi
technolog
teng
et
al
casali
et
al
wasserman
et
al
product
monoclon
antibodi
larg
quantiti
tradit
done
ascit
fluid
mice
usual
balbc
although
monoclon
contamin
varieti
mous
protein
suffici
concentr
use
purpos
without
purif
howev
asciticfluid
method
plagu
limit
search
altern
expertis
gain
develop
bacteri
cultiv
system
begin
appli
cultiv
mammalian
cell
close
batch
system
open
continuousflow
system
test
sever
new
strategi
avail
immobil
hybrid
cell
supernat
contain
monoclon
antibodi
collect
volum
sever
liter
readili
obtain
special
expertis
requir
oper
system
date
primari
limit
system
rel
low
concentr
antibodi
exhaust
medium
consequ
frequent
need
step
concentr
potenti
contamin
cell
line
particularli
mycoplasma
seriou
concern
cultiv
hybridoma
vitro
mycoplasma
shown
alter
immunoglobulin
synthesi
hendershot
levitt
continu
monitor
cultur
detect
mycoplasma
imper
nucleic
acid
probe
recent
develop
purpos
gsbel
stanbridg
razin
et
al
diagnost
dye
molecular
probe
becom
readili
avail
commerci
supplier
exampl
bioniqu
laboratori
saranac
lake
ny
boehring
mannheim
biochem
indianapoli
genprob
distribut
fisher
scientif
rochest
ny
hana
media
hana
biolog
berkeley
ca
brief
review
shall
attempt
highlight
recent
develop
hybridoma
technolog
seem
offer
practic
advantag
least
show
potenti
practic
use
near
futur
reader
seek
comprehens
inform
current
hybridoma
technolog
monoclon
antibodi
applic
encourag
examin
number
excel
review
milstein
read
deni
et
al
schonherr
houwink
sikora
kshler
westerwoudt
depinho
et
al
seek
inform
gener
hybridoma
consult
articl
detail
technolog
oi
herzenberg
milstein
kshler
bastin
et
al
lane
et
al
nakamura
et
al
campbel
gode
sinc
earli
day
cell
cultur
necess
serum
supplement
acknowledg
cole
et
al
darfler
insel
kovar
franek
cleveland
et
al
kawamoto
et
al
mchugh
et
al
steimer
c
effort
reduc
depend
upon
supplement
variou
degre
success
work
laboratori
shown
hybridoma
frequent
grown
less
serum
supplement
often
specifi
medium
formula
appropri
period
acclim
final
serum
concentr
success
util
month
rare
deterior
cultur
viabil
monoclon
antibodi
product
macario
dugan
unpublish
data
advent
hybridoma
technolog
come
renew
interest
chemic
defin
media
mani
reason
motiv
cell
culturist
especi
need
elimin
variat
serum
composit
vendor
lot
vendor
supplement
cultur
medium
compon
enhanc
cell
growth
decreas
probabl
introduc
contamin
virus
mycoplasma
reduc
cost
largescal
oper
concern
specif
product
monoclon
antibodi
hybridoma
includ
time
effort
requir
purifi
antibodi
medium
risk
introduc
compon
may
inhibit
b
lymphocyt
function
hybrid
possibl
crossreact
monoclon
antibodi
produc
compon
medium
last
problem
particular
concern
product
antibodi
compound
natur
occur
anim
human
hormon
enzym
medium
formula
present
tabl
favor
three
compound
transferrin
albumin
insulin
decreas
order
frequenc
cite
compound
formula
add
hormon
testosteron
progesteron
sodium
selenit
boehring
mannheim
hana
biolog
market
media
formul
support
two
murin
myeloma
deriv
well
human
human
hybrid
detail
avail
regard
composit
media
use
studi
review
mchugh
et
al
steimer
ventrex
origin
formul
support
compani
murin
friendli
deriv
broader
applic
claim
manufactur
refer
could
locat
cite
use
tharakan
et
al
compar
growth
murin
hybridoma
hormon
defin
serum
supplement
media
hybrid
test
grew
quickli
serum
supplement
media
tend
produc
less
antibodi
observ
also
made
us
glucos
uptak
could
correl
antibodi
product
ratesthi
lack
correl
emphas
import
monitor
glucos
deplet
antibodi
secret
rate
optim
new
medium
formula
mous
rat
cell
line
current
use
partner
mous
x
mous
mous
x
rat
rat
x
mous
human
x
mous
fusion
list
tabl
ii
produc
antibodi
encod
gene
receiv
b
cell
partner
fusion
synthes
kappa
chain
secret
howev
hybrid
obtain
express
differ
combin
chain
includ
myeloma
b
lymphocyt
line
frequent
use
anoth
line
also
commonli
use
disadvantag
secret
kappa
gamma
chain
line
origin
clone
less
wide
util
atcc
foxni
taggart
samloff
take
advantag
doubl
defici
make
line
sensit
hypoxanthineaminopterinthymidin
hat
adenineaminopterin
shulman
et
al
kshier
milstein
kshler
milstein
taggart
samloff
galfr
et
al
lane
kilmartin
et
al
b
hypoxanthineaminopterinthymidin
american
type
cultur
collect
parklawn
dr
rockvil
md
adenineaminopterinthymidin
e
refer
could
found
croce
et
al
massicott
et
al
eisenbarth
et
al
read
kozbor
et
al
kozbor
roder
kozbor
et
al
abram
et
al
glassi
et
al
deni
et
al
ii
heitzmann
cohn
edward
et
al
nilsson
et
al
matsuoka
et
al
buck
et
al
olsson
kaplan
posner
et
al
hashizum
et
al
ohashi
et
al
ichimori
et
al
c
hat
hypoxanthineaminopterinthymidin
hato
hypoxanthineaminopterinthymidineouabain
e
hazt
f
atcc
american
type
cultur
collect
thymidin
aat
select
rbfdn
mice
requir
obtain
optimum
result
line
expens
balbc
mice
commonli
use
avail
larg
quantiti
without
signific
delay
one
studi
found
use
foxni
sinc
introduct
work
balbc
mice
use
foxni
cell
lane
friendli
rel
new
quit
similar
foxni
accord
supplier
line
use
either
balbc
mice
tradit
hat
select
system
rbfdn
mice
aat
select
system
found
studi
util
cell
supplier
claim
use
sever
larg
compani
well
group
nih
cell
avail
short
time
may
yet
wide
known
rat
myeloma
nonsecret
deriv
fusion
line
ao
spleen
cell
cell
somewhat
larger
appear
grow
slightli
better
origin
line
atcc
propon
rat
myeloma
rat
rat
rat
human
hybrid
claim
greater
stabil
antibodi
yield
clark
et
al
spite
claim
hybridoma
made
rat
myeloma
cell
wide
util
may
due
part
difficulti
encount
tri
grow
rat
hybridoma
galfr
milstein
gode
van
snick
et
al
recent
isol
cellderiv
lymphokin
found
necessari
vitro
cultiv
rat
mous
hybrid
similar
requir
macrophagederiv
factor
support
vitro
growth
plasmacytoma
cell
also
report
nordan
potter
understand
factor
regul
vitro
growth
rat
hybridoma
may
contribut
make
system
wide
util
develop
cell
line
use
prepar
human
x
human
hybridoma
area
great
interest
potenti
clinic
signific
applic
also
interest
genet
problem
studi
human
x
human
system
hunter
line
becom
avail
thu
far
primarili
lymphoblastoid
origin
rather
myeloma
hybrid
characterist
lymphoblast
matur
malign
cell
tabl
iii
notabl
except
gm
deriv
rpmi
line
avail
year
line
gm
continu
use
gener
human
human
hybrid
day
howev
abil
rpmi
form
stabl
hybrid
question
abram
et
al
remain
lymphoblastoid
line
support
none
wide
util
except
humancel
fusion
partner
suffer
disadvantag
secret
parent
heavi
light
chain
antibodi
nonsecretor
produc
stabl
hybrid
grew
well
month
abram
et
al
line
repres
break
tradit
approach
new
line
fusion
partner
develop
clone
establish
line
hybrid
human
myeloma
secret
antibodi
fuse
lymphocyt
plasma
cell
leukemia
fusion
produc
line
secret
heavi
light
chain
antibodi
posner
addit
cell
line
type
develop
high
fusion
effici
maintain
antibodi
product
year
posner
person
commun
similar
effort
made
produc
nonsecret
hybrid
fusion
partner
murin
myeloma
human
cell
ostberg
pursh
teng
et
al
cell
line
use
reli
defect
hypoxanthin
phosphoribosyl
transferas
salvag
pathway
increas
number
antibodysecret
hybrid
obtain
substitut
azaserin
aminopterin
edward
et
al
buck
et
al
ad
ouabain
kozbor
et
al
rodent
system
immun
lymphocyt
usual
gener
inject
host
desir
antigen
suffici
time
proper
boost
enhanc
respons
spleen
anim
contain
antibodysecret
b
lymphocyt
cell
suspens
thu
obtain
usual
need
enrich
fuse
myeloma
line
case
howev
immunogen
particular
determin
low
essenti
three
strategi
develop
improv
respons
weak
antigen
minor
determin
complex
immunogen
thu
increas
number
relev
b
lymphocyt
immunogen
adsorb
onto
matrix
nitrocellulos
introduc
host
sternick
sturmer
knudsen
splenocyt
harvest
immun
donor
reinject
along
antigen
syngen
irradi
recipi
spleen
cell
second
host
harvest
fusion
myeloma
partner
procedur
yield
antibodysecret
hybrid
obtain
usual
techniqu
siraganian
et
al
enhanc
respons
particular
determin
mixtur
also
develop
anim
depress
respons
toward
determin
interest
select
reduct
respons
achiev
either
inject
cytotox
agent
cyclophosphamid
immunogen
matthew
patterson
passiv
immun
recipi
antibodi
direct
toward
undesir
determin
thalham
freund
due
ethic
consider
immun
human
b
lymphocyt
prepar
anim
system
mani
antigen
interest
use
immun
patient
even
case
immun
accept
primari
sourc
antibodysecret
b
lymphocyt
frequent
peripher
blood
techniqu
develop
handl
prepar
peripher
blood
lymphocyt
pbl
fusion
techniqu
summar
tabl
iv
pbl
isol
whole
blood
donor
centrifug
lymphocyt
separ
medium
ficollhypaqu
pharmacia
piscataway
n
j
subsequ
step
increas
risk
cultur
contamin
increas
product
hybrid
greater
stabil
antibodi
secret
may
outweigh
risk
enrich
b
gigliotti
et
al
maeda
et
al
borrebaeck
ho
et
al
read
wasserman
et
al
schell
deni
et
al
heitzmann
cohn
kozbor
roder
westerwoudt
effro
et
al
kozbor
et
al
kozbor
roder
room
read
thompson
et
al
lymphocyt
popul
although
alway
essenti
achiev
use
adher
maeda
et
al
roset
gigliotti
et
al
properti
variou
subgroup
lymphocyt
increas
number
antibodysecret
hybrid
produc
fusion
recent
work
mous
cell
hada
theilen
suggest
use
low
hybridcel
concentr
primari
cultur
fusion
tend
favor
develop
antibodysecret
clone
instanc
approach
may
help
reduc
number
purif
step
requir
prior
fusion
host
immun
imposs
respons
immunogen
must
heighten
pbl
stimul
vitro
expos
antigen
variou
length
time
procedur
often
requir
complex
media
addit
dextran
sulfat
enhanc
respons
pbl
schell
thymocytecondit
medium
improv
respons
murin
spleen
cell
takahashi
et
al
extens
review
vitro
immun
avail
read
borrebaeck
earli
work
shown
primari
secondari
longterm
respons
elicit
vitro
anim
model
macario
et
al
conway
de
macario
macario
recent
vitro
method
appli
nonhuman
system
solubl
immunogen
low
van
ness
et
al
immunogen
weak
rathjen
underwood
mitogenactiv
b
lymphocyt
use
hybrid
anim
model
system
incub
pbl
activ
pokewe
mitogen
deni
et
al
help
instanc
stimul
quiescent
b
cell
prior
fusion
b
lymphocyt
also
activ
incub
epsteinbarr
viru
commonli
use
techniqu
prepar
immort
b
lymphocyt
discuss
greater
length
work
kozbor
et
al
roder
room
read
casali
et
al
velez
et
al
lymphocyt
myeloma
partner
kthler
et
al
later
year
polyethylen
glycol
peg
use
instead
viru
object
rais
use
peg
toxic
cell
altern
suggest
nonetheless
review
recent
literatur
show
widespread
use
form
peg
gener
hybridoma
major
report
detail
procedur
specifi
fuse
peg
oi
herzenberg
milstein
kthler
gode
mechan
involv
pegmedi
cell
fusion
continu
studi
necess
close
contact
cell
fuse
document
knutton
pasternak
wojcieszyn
et
al
peg
appear
promot
close
apposit
cell
membran
addit
contain
commerci
prepar
actual
stimul
fusion
process
wojcieszyn
et
al
may
help
explain
fuse
effici
differ
much
variou
brand
molecular
weight
lot
peg
use
fazeka
de
stgroth
scheidegg
lane
et
al
compound
dimethyl
sulfoxid
use
modifi
cell
membran
enhanc
fusion
fazeka
de
stgroth
scheidegg
synchron
cell
cycl
colcemid
produc
myeloma
cell
stage
report
miyahara
et
al
none
techniqu
wide
adopt
immunochem
method
appli
fusion
mixtur
effort
guid
immun
lymphocyt
myeloma
cell
latter
cell
coat
antigen
kranz
et
al
hapten
lo
et
al
react
immun
lymphocyt
without
peg
bankert
et
al
appar
eleg
techniqu
found
frequent
use
entir
differ
approach
fuse
cell
electrofus
propos
late
zimmerman
scheurich
bischoff
et
al
cell
orient
nonuniform
electr
field
fuse
appli
puls
highfrequ
energi
like
immunochem
method
electrofus
becom
popular
found
one
paper
report
success
construct
antibodysecret
hybridoma
electrofus
alon
bischoff
et
al
howev
electrofus
success
combin
immunochem
method
lo
et
al
biotinavidin
techniqu
direct
b
lymphocytemyeloma
cell
aggreg
increas
hybridoma
yield
wojchowski
sytkowski
high
cost
equip
necessari
techniqu
may
partli
explain
rather
limit
util
feeder
cell
layer
routin
use
hybridoma
technolog
support
growth
newli
fuse
hybrid
singl
ceil
clone
periton
macrophag
fazeka
de
stgroth
scheidegg
splenocyt
gode
thymocyt
oi
herzenberg
employ
provid
unknown
factor
enhanc
growth
hybrid
cell
although
enhanc
effect
auxiliari
feeder
cell
longterm
antibodi
synthesi
vitro
report
variou
system
includ
rabbit
lymph
node
model
conway
de
macario
macario
introduct
cell
hybridoma
technolog
rais
sever
concern
sinc
feeder
cell
prepar
tissu
remov
anim
donor
possibl
hybridoma
becom
contamin
bacteria
fungi
mycoplasma
introduc
feeder
cell
increas
feeder
cell
compet
hybrid
cell
metabolit
increas
deplet
rate
medium
addit
cell
number
increas
rate
metabol
wast
accumul
may
prove
inhibitori
hybrid
feeder
cell
usual
normal
somat
cell
divid
surviv
long
period
time
cultur
slowgrow
hybridoma
cell
requir
feeder
layer
replenish
new
cell
increas
probabl
contamin
also
increas
probabl
dead
cell
left
cultur
releas
autolyt
enzym
may
damag
either
hybridoma
cell
antibodi
develop
altern
feeder
cell
slow
come
recent
studi
shown
condit
medium
establish
macrophag
cell
line
effect
support
vitro
growth
plasmacytoma
cell
nordan
potter
condit
medium
enhanc
establish
hybridoma
fusion
also
clone
effici
hybrid
clone
limit
dilut
rathjen
greczi
furthermor
van
snick
et
al
report
isol
tcell
deriv
lymphokin
support
vitro
growth
rat
mous
hybrid
otherwis
fail
surviv
continu
investig
along
line
lead
develop
well
defin
addit
latter
could
includ
serumfre
media
formula
improv
perform
stage
hybridoma
cultiv
product
high
concentr
monoclon
antibodi
ascit
fluid
wellestablish
techniqu
oi
herzenberg
milstein
bastin
et
al
laboratori
system
yield
antibodi
concentr
averag
mgml
ml
ascit
fluid
per
mous
ascit
usual
develop
within
week
murin
host
hybridoma
often
balbc
prepar
singl
intraperiton
inject
pristan
mous
mous
hybridoma
use
pristan
elimin
without
deminish
concentr
antibodi
recov
macario
dugan
unpublish
data
increas
need
larg
quantiti
nonmurin
antibodi
elabor
method
develop
prepar
host
hybridoma
tabl
v
one
problem
vivo
gener
host
reject
hybridoma
minim
reject
mice
irradi
although
optim
radiat
dose
vari
system
use
suppress
host
immun
system
manner
appear
allevi
host
reject
hybridoma
immun
respons
antibodi
kozbor
et
al
weissman
et
al
anoth
problem
encount
vivo
gener
need
hybridoma
adapt
complex
environ
host
periton
caviti
passag
subcutan
tumor
truitt
et
al
weissman
et
al
raybould
et
al
raybould
et
al
kozbor
et
al
truitt
et
al
yarmush
et
al
noeman
et
al
hirsch
et
al
b
cell
adapt
subcutan
implant
irradi
mice
prior
intraperiton
inject
ascit
product
cell
adapt
intraven
inject
rat
prior
intraperiton
inject
ascit
product
kozbor
et
al
growth
liver
tissu
hirsch
et
al
prove
use
establish
hybridoma
vivo
stabil
secret
antibodi
ascit
tumor
even
difficulti
produc
monoclon
antibodi
ascit
fluid
resolv
puriti
may
remain
problem
subsequ
purif
techniqu
must
appli
whenev
asciticfluid
impur
inconveni
eg
therapeut
trial
techniqu
vari
complex
gener
step
incorpor
attain
desir
level
puriti
lower
final
yield
dalchau
fabr
bazin
et
al
macario
dugan
unpublish
result
use
larg
number
anim
produc
substanti
volum
ascit
fluid
requir
appropri
facil
special
staff
develop
vitro
cultiv
techniqu
product
monoclon
antibodi
come
major
endeavor
hybridoma
technolog
current
avail
lowserum
serumfre
media
discuss
make
optim
cultiv
system
feasibl
potenti
paramet
modif
includ
ga
exchang
mechan
forc
act
cell
fluid
dynam
rate
nutrient
consumpt
mean
regul
feed
wast
product
accumul
effect
cell
growth
secret
effect
temperatur
pressur
feder
tolbert
glacken
et
al
gruenberg
walker
birch
et
al
reuveni
et
al
b
must
reiter
goal
optim
high
product
secret
ie
monoclon
antibodi
rapid
growth
produc
cell
gener
procedur
use
tabl
vi
divid
smallscal
system
laboratoryscal
unit
commerci
mass
product
smallscal
product
includ
system
stationari
cultur
flask
roller
bottl
techniqu
readili
avail
laboratori
tissu
cultur
effect
produc
small
quantiti
liter
antibodycontain
media
sever
clone
simultan
garberi
et
al
also
frequent
use
maintain
hybrid
line
laboratoryscal
unit
state
rapid
develop
unit
vitafib
ii
amicon
dynacel
cultur
system
millipor
acusystjr
endotron
intend
product
liter
batch
antibodycontain
medium
period
month
medium
chang
weekli
biweekli
gener
commerci
literatur
claim
laboratoryscal
unit
produc
higher
concentr
antibodi
stationari
flask
system
dynacel
system
found
claim
true
macario
dugan
unpublish
data
also
includ
categori
smaller
airlift
fermentor
stir
cultur
system
develop
benchtop
oper
control
unit
becom
sophist
wernerspach
laboratoryscal
unit
particularli
suit
expans
small
number
hybrid
particular
interest
develop
larger
commercialscal
unit
base
mostli
upon
experi
cultiv
bacteria
product
run
excess
cleveland
et
al
galfr
milstein
ostberg
pursch
bodeu
et
al
sjsgrenjansson
jeansson
reuveni
et
al
reuveni
et
al
velez
et
al
birch
et
al
nilsson
et
al
scheirer
et
al
seaver
et
al
weimann
et
al
altshul
et
al
liter
uncommon
airlift
stir
cultur
system
usual
employ
special
equip
techniqu
maintain
uniform
temperatur
ph
nutrient
suppli
remov
cell
wast
andor
undesir
product
klausner
bloom
system
intend
averag
research
laboratori
product
monoclon
antibodi
diagnost
therapeut
applic
must
also
compli
govern
regul
may
requir
modif
equip
andor
procedur
zimmerman
et
al
henc
choos
vitro
cultiv
system
one
must
consid
volum
product
desir
intend
use
product
well
space
fund
avail
gener
human
human
hybridoma
hinder
degre
absenc
appropri
fusion
partner
grow
well
produc
stabl
hybrid
secret
antibodi
secret
high
level
antibodi
fuse
immun
lymphocyt
hunter
avoid
problem
encount
human
fusion
partner
investig
produc
heterolog
hybrid
use
well
establish
murin
fusion
partner
tabl
vii
interspeci
hybrid
often
plagu
instabl
result
chromosom
incompat
human
chromosom
import
sustain
product
monoclon
antibodi
appear
particularli
suscept
reduc
possibl
loss
investig
fuse
murin
myeloma
nonimmun
human
cell
prior
use
hybrid
fusion
partner
immun
lymphocyt
ostberg
pursch
teng
et
al
hybrid
fusion
partner
requir
consider
time
gener
appear
produc
stabl
hybridoma
slightli
higher
secret
rate
nonhybrid
murin
myeloma
whether
use
murin
fusion
partner
produc
human
x
mous
hybrid
favor
develop
iggsecret
clone
determin
sinc
public
report
screen
hybrid
product
singl
class
antibodi
although
murin
hybridoma
system
wide
use
model
produc
studi
hybridoma
product
anim
system
also
investig
sherman
markham
murin
myeloma
often
mous
x
human
heteromyeloma
use
fusion
partner
immun
lymphocyt
bovin
porcin
ovin
rabbit
monkey
chimpanze
origin
tabl
viii
anim
scientif
veterinari
possibl
clinic
import
anim
host
immun
vivo
addit
stimul
use
prior
fusion
hybrid
nonprim
immun
lymphocyt
show
stabl
antibodi
pro
teng
et
al
gigliotti
et
al
maeda
et
al
thompson
et
al
lane
et
al
ostberg
pursch
weissman
et
al
raybould
et
raybould
et
al
yarmush
et
grove
et
al
van
meur
jonker
van
meel
et
al
b
ig
chain
variou
allotyp
duction
sever
month
could
cultur
balbc
mice
produc
antibodi
ascit
fluid
murin
antibodi
monoclon
bovin
porcin
antibodi
ascit
fluid
prove
signific
contamin
hybrid
primat
lymphocyt
fuse
murin
myeloma
much
less
stabl
fuse
heteromyeloma
van
meel
et
al
van
meur
jonker
monoclon
antibodi
direct
toward
speci
easili
envis
applic
veterinari
medicin
similar
applic
human
monoclon
antibodi
sherman
markham
product
hybridoma
secret
primat
monoclon
antibodi
may
also
import
clinic
applic
immunotherapi
use
monoclon
antibodi
murin
origin
tend
elicit
immun
respons
therapeut
agent
applic
immunosuppress
therapi
often
requir
extend
exposur
antibodi
becom
less
effect
patient
produc
antibodi
murin
antibodi
antibodi
primat
origin
may
prove
far
less
immunogen
particularli
case
fab
fragment
use
